How long can you stay on semaglutide for weight loss?

Step 1, understanding what the licence does (and does not) say

Wegovy's UK licence, granted by the MHRA, approves semaglutide for weight management in adults with a BMI of 30 or above, or 27 or above alongside a weight-related health condition such as high blood pressure or type 2 diabetes. The licence does not specify a hard stop date. What it requires is that treatment continues only while the person is responding and tolerating it well. A prescriber is expected to review that picture regularly.

One misconception worth clearing up: many people assume that GLP-1 medicines are inherently short-term treatments, a course, like antibiotics. They are not. Obesity is a long-term condition, and the medicines that treat it are designed with that in mind. If you are wondering how long you can be on semaglutide, the answer depends on your clinical picture rather than any fixed countdown. Duration is a clinical conversation, not a countdown.

The NHS patient information for semaglutide explains the general principles of how the medicine works and what to discuss with your prescriber about ongoing use. For the exact terms of the licensed indication, the Mounjaro SmPC on the eMC is the authoritative document for tirzepatide; for semaglutide the equivalent eMC listing applies.

Step 2, how NICE guidance shapes NHS duration

On the NHS, access to Wegovy is governed by NICE technology appraisal TA875, which recommends semaglutide only within specialist weight management services and places a clear time boundary on funded treatment: a maximum of two years. It also states that if a person has not lost at least 5% of their starting weight after six months on the full maintenance dose, continuing is unlikely to be appropriate.

That two-year ceiling applies specifically to NHS-funded treatment through specialist services. It does not automatically translate into a clinical verdict that semaglutide stops working or becomes unsafe after 24 months, it reflects how the NHS has chosen to commission and prioritise the medicine given finite resources.

Private prescribing operates under the medicine's licence rather than TA875's commissioning constraints, which is why a GPhC-registered prescriber on a private pathway can support treatment beyond two years if it remains clinically suitable. The question of long-term Wegovy use is one our prescribers discuss with patients regularly, and the answer is always individual.

Step 3, what happens when you stop

This is the part most people are not told clearly enough upfront. When semaglutide is stopped, the appetite-regulating effect fades. Clinical trial follow-up data consistently show that a substantial proportion of weight lost during treatment is regained within 12 months of stopping, not because anything went wrong, but because the biological mechanism that suppressed appetite is no longer active.

The STEP 1 extension study, published in the New England Journal of Medicine, followed participants after they stopped semaglutide 2.4mg and found that, within a year of discontinuation, much of the weight lost during the 68-week trial had returned. Lifestyle changes made during treatment tend to persist better than the weight loss itself, but they do not fully compensate for losing the medicine's effect on appetite.

This is not a reason to avoid treatment. It is a reason to plan ahead with your prescriber, to think about what structured lifestyle support looks like alongside the medicine, and what the longer-term picture might be if and when you do stop. If you are thinking about how long most people actually stay on semaglutide for weight loss, the honest answer is that there is no single typical duration: it varies by response, by health goals, and by whether treatment is NHS or private. Our guide on how long semaglutide treatment tends to last walks through the factors that shape that decision in more detail.

Step 4 (what a prescriber looks at when reviewing continuation

At every clinical review) whether that is a routine check-in or a repeat prescription assessment, a prescriber will weigh several things. Is the person continuing to benefit in terms of weight or health markers? Are side effects manageable? Has the person's health situation changed in a way that affects suitability? Are there new medicines or conditions that interact with semaglutide?

At nume, every repeat order goes through a fresh clinical assessment by a GPhC-registered prescriber, a real clinician reads your notes, not software running a checklist. There are no automatic renewals. That approach is by design: for ongoing semaglutide treatment, responsible continuation matters as much as responsible initiation.

If you are weighing up whether private treatment is the right route, or want to understand what our prescribers consider before approving each repeat, you can find more on our about us page or explore our approach to weight loss more broadly. For a full picture of treatment options, our free consultation page is the place to start, a prescriber can look at your specific situation and give you a clear answer about what duration of treatment makes sense for you.